ISDA

Deposition Date 2022-02-10

Release Date 2022-03-23

Last Version Date 2024-11-20

Entry Detail

PDB ID:

7R52

Keywords:

IMMUNE SYSTEM

Title:

Crystal structure of human TLR8 in complex with Compound 2

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Drosophila melanogaster

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.94 Å

R-Value Free:

0.27

R-Value Work:

0.25

R-Value Observed:

0.25

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Toll-like receptor 8
Gene (Uniprot):TLR8
Chain IDs:A, B
Chain Length:807
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q9NR97 Pfam ID:PF13855

Ligand Molecules

I6A

NAG

Primary Citation

Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an In Vivo Efficacious TLR7/8 Antagonist.

Betschart, C, Faller, M, Zink, F, Hemmig, R, Blank, J, Vangrevelinghe, E, Bourrel, M, Glatthar, R, Behnke, D, Barker, K, Heizmann, A, Angst, D, Nimsgern, P, Jacquier, S, Junt, T, Zipfel, G, Ruzzante, G, Loetscher, P, Limonta, S, Hawtin, S, Andre, C.B, Boulay, T, Feifel, R, Knoepfel, T.Show

Acs Med.Chem.Lett. 13 658 664 (2022)

PMID: 35450354 DOI: 10.1021/acsmedchemlett.1c00696

Abstact

Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. Here we report on the efficient structure-based optimization of the inhibition of TLR8, starting from a co-crystal structure of a small screening hit. Further optimization of the physicochemical properties for cellular potency and expansion of the structure-activity relationship for dual potency finally resulted in a highly potent TLR7/8 antagonist with demonstrated in vivo efficacy after oral dosing.

Legend

Protein

Chemical

Disease

Primary Citation of related structures